# Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

> **NCT00090675** · PHASE3 · WITHDRAWN · sponsor: **AstraZeneca**

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **DRUG:** ZD1839

## Key facts

- **NCT ID:** NCT00090675
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-01
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients randomised
- **Last updated:** 2013-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00090675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00090675, "Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00090675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*